Laila König1, Robert Stade2, Juliane Rieber2, Jürgen Debus2, Klaus Herfarth2. 1. Abteilung RadioOnkologie und Strahlentherapie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland. Laila.Koenig@med.uni-heidelberg.de. 2. Abteilung RadioOnkologie und Strahlentherapie, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Deutschland.
Abstract
PURPOSE: The aim of this work was to retrospectively analyze efficacy, toxicity, and relapse rates of conventional (CRT) and low-dose radiotherapy (LDRT) in patients with indolent orbital lymphomas. PATIENTS AND METHODS: From 1987-2014, 45 patients (median age 64 years) with 52 lesions of indolent orbital lymphomas were treated with CRT (median dose 36 Gy, range 26-46 Gy) and 7 patients (median age 75 years) with 8 lesions were treated with LDRT (2 fractions of 2.0 Gy). RESULTS: Median follow-up was 133 months (range 2-329 months) in the CRT group and 25 months (range 10-41 months) in the LDRT group. Overall response rates were 97.7 % (CRT) and 100 % (LDRT). The 2‑ and 5‑year local progression-free survival (PFS) rates were 93.5 and 88.6 %, distant PFS 95.0 and 89.9 %, and overall survival 100 and 85.6 % after CRT. In the LDRT group, 2‑year local PFS and overall survival remained 100 %, respectively, and distant PFS 68.6 %. Acute radiotherapy-related complications (grades 1-2) were detected in virtually all eyes treated with CRT. Cataracts developed in only patients who were irradiated with more than 34 Gy. LDRT was well tolerated with only mild acute and late complications. CONCLUSION: Primary radiotherapy of indolent orbital lymphomas is an effective treatment with high response rates and excellent local control in CRT and LDRT. In combination with close follow-up, LDRT may be an attractive alternative since re-irradiation even with conventional doses is still feasible.
PURPOSE: The aim of this work was to retrospectively analyze efficacy, toxicity, and relapse rates of conventional (CRT) and low-dose radiotherapy (LDRT) in patients with indolent orbital lymphomas. PATIENTS AND METHODS: From 1987-2014, 45 patients (median age 64 years) with 52 lesions of indolent orbital lymphomas were treated with CRT (median dose 36 Gy, range 26-46 Gy) and 7 patients (median age 75 years) with 8 lesions were treated with LDRT (2 fractions of 2.0 Gy). RESULTS: Median follow-up was 133 months (range 2-329 months) in the CRT group and 25 months (range 10-41 months) in the LDRT group. Overall response rates were 97.7 % (CRT) and 100 % (LDRT). The 2‑ and 5‑year local progression-free survival (PFS) rates were 93.5 and 88.6 %, distant PFS 95.0 and 89.9 %, and overall survival 100 and 85.6 % after CRT. In the LDRT group, 2‑year local PFS and overall survival remained 100 %, respectively, and distant PFS 68.6 %. Acute radiotherapy-related complications (grades 1-2) were detected in virtually all eyes treated with CRT. Cataracts developed in only patients who were irradiated with more than 34 Gy. LDRT was well tolerated with only mild acute and late complications. CONCLUSION: Primary radiotherapy of indolent orbital lymphomas is an effective treatment with high response rates and excellent local control in CRT and LDRT. In combination with close follow-up, LDRT may be an attractive alternative since re-irradiation even with conventional doses is still feasible.
Entities:
Keywords:
Indolent non-Hodgkin lymphoma; Local progression-free survival; Low-dose radiotherapy; Orbital lymphoma; Treatment outcome
Authors: Marc Bischof; Michael Karagiozidis; Robert Krempien; Martina Treiber; Dirk Neuhof; Jürgen Debus; Dietmar Zierhut Journal: Strahlenther Onkol Date: 2007-01 Impact factor: 3.621
Authors: T W Bolek; H M Moyses; R B Marcus; L Gorden; R L Maiese; N M Almasri; N P Mendenhall Journal: Int J Radiat Oncol Biol Phys Date: 1999-04-01 Impact factor: 7.038
Authors: Andrea L Russo; Yu-Hui Chen; Neil E Martin; Anant Vinjamoori; Sarah K Luthy; Arnold Freedman; Evan M Michaelson; Barbara Silver; Peter M Mauch; Andrea K Ng Journal: Int J Radiat Oncol Biol Phys Date: 2013-02-12 Impact factor: 7.038
Authors: N Cassoux; H Merle-Beral; V Leblond; B Bodaghi; D Miléa; S Gerber; C Fardeau; I Reux; K H Xuan; C C Chan; P LeHoang Journal: Ocul Immunol Inflamm Date: 2000-12 Impact factor: 3.070
Authors: Carolina E Fasola; Jennifer C Jones; Derek D Huang; Quynh-Thu Le; Richard T Hoppe; Sarah S Donaldson Journal: Int J Radiat Oncol Biol Phys Date: 2013-05-29 Impact factor: 7.038
Authors: Gustavo R Sarria; Carla M Cabrera; Gustavo J Sarria; Mario Buitrago; Paola Fuentes; Solon Serpa; Frank A Giordano Journal: J Contemp Brachytherapy Date: 2020-06-30
Authors: Michel Zimmermann; Christoph Oehler; Ulrich Mey; Pirus Ghadjar; Daniel Rudolf Zwahlen Journal: Radiat Oncol Date: 2016-08-30 Impact factor: 3.481